A new design for bispecific antibodies enables efficient production of stable molecules with good pharmacodynamic properties.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wu, C.Y.H., Grinnell, C. & Bryant, S. Nat. Biotechnol. 25, 1290–1297 (2007).
Milstein, C. & Cuello, A.C. Nature 305, 537–540 (1983).
Carter, P. J. Immunol. Methods 248, 7–15 (2001).
Holliger, P., Prospero, T. & Winter, G. Proc. Natl. Acad. Sci. USA 90, 6444–6448 (1993).
Pack, P., Muller, K., Zahn, R. & Pluckthun, A. J. Mol. Biol. 246, 28–34 (1995).
Pack, P. & Pluckthun, A. Biochemistry 31, 1579–1584 (1992).
Natsume, A. et al. J. Biochem. 140, 359–368 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, S. Two heads are better than one. Nat Biotechnol 25, 1233–1234 (2007). https://doi.org/10.1038/nbt1107-1233
Issue Date:
DOI: https://doi.org/10.1038/nbt1107-1233
This article is cited by
-
Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats
Current Medical Science (2020)
-
Cytokines in inflammatory bowel disease
Nature Reviews Immunology (2014)